Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of "Moderate Buy" from Brokerages

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $56.33.

A number of research analysts have weighed in on the company. Royal Bank of Canada increased their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an "outperform" rating in a report on Tuesday. StockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, November 9th. Scotiabank lifted their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a research report on Monday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Finally, Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 27th.

Agios Pharmaceuticals Stock Down 5.8 %

AGIO traded down $2.65 during midday trading on Wednesday, hitting $43.37. 961,709 shares of the company traded hands, compared to its average volume of 710,675. The company's 50-day moving average is $50.09 and its 200 day moving average is $46.68. Agios Pharmaceuticals has a 52 week low of $20.96 and a 52 week high of $62.58. The firm has a market capitalization of $2.47 billion, a PE ratio of 4.05 and a beta of 0.80.

Insider Activity at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of the company's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares of the company's stock, valued at $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.93% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at approximately $37,000. Quest Partners LLC purchased a new stake in Agios Pharmaceuticals during the 2nd quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 363 shares during the last quarter. CWM LLC boosted its stake in Agios Pharmaceuticals by 554.7% during the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 1,836 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in shares of Agios Pharmaceuticals in the third quarter valued at $146,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.